---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-042118"
form_type: "8-K"
ticker: "QTRX"
cik: "0001503274"
company_name: "Quanterix Corp"
filed_at: "2024-10-03T23:59:59+00:00"
generated_at: "2026-05-30T21:26:20.673101+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Quanterix appoints Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors

## Summary
- Dr. Magovčević-Liebisch appointed effective Oct 2, 2024 as Class III director with term expiring at 2026 annual meeting.
- Received initial equity award valued at $400,000 (60% stock options, 40% RSUs) vesting over three years.
- She serves as President and CEO of Vigil Neuroscience, with over 25 years biopharma experience.
- Appointed to the Compensation Committee of the Board.

## SEC filing metadata
- accession: 0001628280-24-042118
- form_type: 8-K
- ticker: QTRX
- cik: 0001503274
- company_name: Quanterix Corp
- filed_at: 2024-10-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503274/000162828024042118/0001628280-24-042118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503274/000162828024042118/qtrx-20241002.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-042118
- JSON: https://secwatch.observer/filing/0001628280-24-042118.json
- Plain text: https://secwatch.observer/filing/0001628280-24-042118.txt

## Key facts
- Executive change
  Ivana Magovčević-Liebisch was appointed as Director at Quanterix Corp.
  - Action: appointed
  - Role: Director
  source text: appointed Ivana Magovčević-Liebisch, Ph.D., J.D. to serve on the Board effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503274/000162828024042118/0001628280-24-042118-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.